Document is current
Any future updates will be listed below
-
Authors
Karagiannidis, Artemios G. https://orcid.org/0000-0002-7054-1422
Theodorakopoulou, Marieta P. https://orcid.org/0000-0001-6216-9635
Iatridi, Fotini https://orcid.org/0000-0001-8863-227X
Ortiz, Alberto https://orcid.org/0000-0002-9805-9523
Sarafidis, Pantelis https://orcid.org/0000-0002-9174-4018
- License Information
-
More Information
Article History
Received: 13 September 2024
Revised: 27 February 2025
Accepted: 21 March 2025
First Online: 31 March 2025
Competing interests
: AO has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Bioporto, Boehringer Ingelheim, Esteve, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma and is Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes. He has stock in Telara Farma. All of the other authors disclose that they do not have any financial or other relationships, which might lead to a conflict of interest regarding this paper.
